157284-96-3

Basic information

• Product Name: N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• Synonyms: 7H-pyrrolo[2,3-d]pyrimidin-4-amine, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-; N-Butyl-N-ethyl-7-mesityl-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• CAS NO: 157284-96-3
• Molecular Formula: C₂₄H₃₄N₄
• Molecular Weight: 378.5536
• Mol File: 157284-96-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 437.2°C at 760 mmHg
• Flash Point: 218.2°C
• Density: 1.05g/cm³
• Vapor Pressure: 7.63E-08mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: 2-8°C
• Solubility: DMSO: ~24?mg/mL, soluble
• PKA: 7.10±0.30(Predicted)
• CAS DataBase Reference: N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine(157284-96-3)
• EPA Substance Registry System: N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine(157284-96-3)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 157284-96-3(Hazardous Substances Data)

Relevant articles and documents

Pyrrolopyrimidines as CRF antagonists

The compounds of the formula wherein R1, R2, R3, R4, R5and R6are as defined herein, are useful in the treatment of stress-related and other diseases. These compounds have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of stress and anxiety related, and other disorders.

QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death

A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.

PYRAZOLOPYRIMIDINES FOR TREATMENT OF CNS DISORDERS

This invention relates to the use of pyrazolopyrimidines and pyrrolopyrimidine of, respectively, the general formula STR1 wherein A, X, R 3, R 4 and R 5 are as defined below, and the pharmaceutically acceptable salts of such compounds, to treat, prevent or inhibit certain neuronal and other disorders.